Compared to those randomized to TAU, OLP participants reported a 29% improvement in fatigue severity (average difference in the mean change scores (MD) 12.47, 95% CI 3.32, 21.61; P = 0.008), medium effect (d = 0.63), and a 39% improvement in fatigue-disrupted quality of life (MD = 11.76, 95% CI 4.65, 18.86; P = 0.002), a large effect (d = 0.76).
These characteristics included headache frequency, severity, average duration, school absences, and overall perceived response to treatment (Table 1).
The patients had a range of visual field defect severity: average HFA mean defect (MD) was -8.0 (SD = 8.8) dB, -5.4 (SD = 5.7) dB and -8.9 (SD = 8.6) in the right eye, left eye and worse eye, respectively.
Following treatment with mesalazine but not placebo, there seemed to be significant improvement in average abdominal pain severity, average urgency score and average daily stool consistency (see figure 4 and online supplementary figure S2).
There was also a mean reduction in pain severity (average of 4 severity items on the Brief Pain Inventory-Short Form) of 0.65 in favor of patients receiving enzalutamide (P < 0.001).
The patients had a range of VF defect severity: average MD was −10.1 (SD: 7.5) dB, –8.2 (SD: 5.2) dB and −5.9 (SD: 5.4) dB in the right eye, left eye and best eye, respectively.
There was no evidence of any differences between the groups in clinical symptoms such as abdominal pain severity, average stool consistency and number of days with stool consistency type 6 7 (table 3).
After statistically controlling for total cortical neuritic plaque severity, average white matter Aβ-42 levels were still higher in AD patients than in non-AD controls (main effect of Group: F 1,14) = 5.184, p = 0.039).
The initial painDETECT-validation study reported a significant association (P<0.001) between pain severity (average over the past 4 weeks) and painDETECT scores, 15 and other studies have confirmed that higher painDETECT scores were significantly associated with greater average pain severity over the previous 4 weeks (P<0.05).
There was no observed change in severity (average dB loss) for the central defect of the 17 study participants who had a central defect at both baseline and randomization (mean 11.5dBB versus 6.7 dB at baseline and randomization, respectively; p = 0.09) after SFC adjustment.
